Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPALAN vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension
100 mg orally twice daily
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is 12-14 hours in adults with normal renal function; prolonged to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 60 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Hepatic via CYP2D6 and CYP3A4; active metabolite N-desmethylserpalan.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Primarily renal elimination (60-70% unchanged drug), with 20-30% biliary/fecal excretion as metabolites; less than 10% excreted unchanged in feces.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Approximately 85-90% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
~90%, primarily to albumin
1.2-1.8 L/kg, indicating extensive tissue distribution (e.g., liver, kidneys, and lungs); higher Vd in obese patients.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 75-85% due to first-pass metabolism; IM: 90-98%; rectal: 50-70%.
Oral: 50–60% (extensive first-pass metabolism)
GFR ≥ 60 m L/min: no adjustment; GFR 30-59 m L/min: 50 mg once daily; GFR < 30 m L/min: avoid use
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily; Child-Pugh C: contraindicated
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Not established for patients < 18 years
Not recommended for pediatric use; safety in children under 12 years not established.
Maximum 50 mg once daily due to increased sensitivity and renal impairment risk
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
Suicidal thoughts and behaviors: Increased risk in children, adolescents, and young adults during initial treatment.
None
Serotonin syndrome with concomitant serotonergic drugs; risk of bleeding with NSAIDs/anticoagulants; activation of mania/hypomania; bone fracture risk in elderly; hyponatremia; QT prolongation at high doses.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to serpalan; concurrent use of MAOIs or linezolid; concurrent use of pimozide; use of MAOIs within 14 days.
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid concurrent use of alcohol; may worsen central nervous system effects. No specific food restrictions; take with or without food. Grapefruit juice has no significant interaction.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Late third trimester: neonatal withdrawal syndrome and respiratory depression.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Excreted into breast milk (M/P ratio 0.9). Not recommended during breastfeeding due to potential adverse effects on infant including sedation, poor feeding, and withdrawal. Consider alternative therapy.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Due to increased plasma volume and hepatic metabolism, dose may need to be increased by 20-30% in the second and third trimesters. Monitor trough levels and adjust to maintain therapeutic range. Postpartum, decrease dose to prepregnancy levels within 48 hours.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
SERPALAN is a selective serotonin reuptake inhibitor (SSRI) used for major depressive disorder. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic drugs. Initiate at 20 mg daily; titrate to 40 mg after 4 weeks if needed. Do not abruptly discontinue; taper gradually to avoid withdrawal symptoms. Use with caution in patients with hepatic impairment (dose reduction recommended). Avoid MAOIs within 14 days.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication at the same time each day, with or without food.,Do not stop taking this medication suddenly; consult your doctor for a tapering schedule.,It may take 2–4 weeks to feel the full benefit; continue taking even if you do not notice immediate improvement.,Notify your doctor if you experience new or worsening anxiety, agitation, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not take other medications, including over-the-counter drugs, without consulting your doctor.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPALAN vs ALDORIL 15, answered by our medical review team.
SERPALAN is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPALAN and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPALAN is: 100 mg orally twice daily. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPALAN and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPALAN is classified as Category C. First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and thir. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.